Symbols / LNTH
LNTH Chart
About
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. It also provides Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; PYLARIFY AI, an medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer; and flurpiridaz used to assess blood flow to the heart. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy to patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent for Tau tangles in Alzheimer's disease; LNTH-2401, a novel radiodiagnostic targeting the gastrin-releasing peptide receptor; LNTH-2402; LNTH-2403; LNTH-2404; and LNTH-1363S, an fibroblast activation protein, alpha, copper-64 labeled PET imaging agent. It has collaboration agreements with GE Healthcare; POINT; Regeneron; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Drug Manufacturers - Spe | Market Cap | 5.10B |
| Enterprise Value | 5.12B | Income | 167.68M | Sales | 1.53B |
| Book/sh | 16.88 | Cash/sh | 5.76 | Dividend Yield | — |
| Payout | 0.00% | Employees | 808 | IPO | — |
| P/E | 31.15 | Forward P/E | 13.63 | PEG | — |
| P/S | 3.35 | P/B | 4.45 | P/C | — |
| EV/EBITDA | 12.54 | EV/Sales | 3.35 | Quick Ratio | 2.21 |
| Current Ratio | 2.67 | Debt/Eq | 55.35 | LT Debt/Eq | — |
| EPS (ttm) | 2.41 | EPS next Y | 5.51 | EPS Growth | -77.10% |
| Revenue Growth | 1.40% | Earnings | 2026-02-26 | ROA | 9.93% |
| ROE | 14.59% | ROIC | — | Gross Margin | 62.23% |
| Oper. Margin | 11.36% | Profit Margin | 10.99% | Shs Outstand | 66.31M |
| Shs Float | 59.54M | Short Float | 9.84% | Short Ratio | 5.93 |
| Short Interest | — | 52W High | 111.29 | 52W Low | 47.25 |
| Beta | -0.09 | Avg Volume | 929.21K | Volume | 234.00K |
| Target Price | $85.00 | Recom | Strong_buy | Prev Close | $73.61 |
| Price | $75.07 | Change | 1.98% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$85.00
Mean price target
2. Current target
$75.07
Latest analyst target
3. DCF / Fair value
$88.88
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$75.07
Low
$70.00
High
$130.00
Mean
$85.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-24 | main | Citizens | Market Outperform → Market Outperform | $78 |
| 2025-12-18 | main | Truist Securities | Buy → Buy | $82 |
| 2025-12-17 | main | Mizuho | Outperform → Outperform | $72 |
| 2025-12-12 | up | Truist Securities | Hold → Buy | $80 |
| 2025-11-10 | reit | Truist Securities | Hold → Hold | $61 |
| 2025-10-08 | down | Goldman Sachs | Buy → Neutral | $77 |
| 2025-09-16 | main | B. Riley Securities | Buy → Buy | $84 |
| 2025-09-15 | main | TD Cowen | Buy → Buy | $80 |
| 2025-08-12 | down | Truist Securities | Buy → Hold | $63 |
| 2025-08-07 | main | JMP Securities | Market Outperform → Market Outperform | $73 |
| 2025-08-07 | main | Mizuho | Outperform → Outperform | $70 |
| 2025-06-23 | main | B. Riley Securities | Buy → Buy | $109 |
| 2025-05-08 | main | Truist Securities | Buy → Buy | $117 |
| 2025-03-21 | main | B. Riley Securities | Buy → Buy | $122 |
| 2025-02-27 | main | Truist Securities | Buy → Buy | $127 |
| 2025-01-14 | reit | JMP Securities | Market Outperform → Market Outperform | $112 |
| 2024-12-18 | init | Goldman Sachs | — → Buy | $143 |
| 2024-11-08 | reit | Truist Securities | Buy → Buy | $120 |
| 2024-11-07 | main | JMP Securities | Market Outperform → Market Outperform | $112 |
| 2024-09-03 | init | Redburn Atlantic | — → Buy | $175 |
- LNTH Stock Surges 13% With A 9-day Winning Spree On Institutional Accumulation - Trefis Fri, 20 Feb 2026 05
- Lantheus Holdings, Inc.'s (NASDAQ:LNTH) Stock Is Going Strong: Is the Market Following Fundamentals? - Yahoo Finance Sun, 01 Feb 2026 08
- Lantheus Earnings: What To Look For From LNTH - FinancialContent Wed, 25 Feb 2026 03
- Lantheus Holdings (LNTH): Analyst Ratings and Price Target Update | LNTH Stock News - GuruFocus ue, 24 Feb 2026 15
- LNTH Stock Surges 13% In A 9-day Spree On Technical Breakout And Bullish Ratings - Trefis Fri, 20 Feb 2026 05
- Lantheus: Management And Competition Raise Real Concern (Rating Downgrade) (NASDAQ:LNTH) - Seeking Alpha Fri, 16 Jan 2026 08
- Lantheus Holdings, Inc. (LNTH) Stock Analysis: Exploring a 57% Potential Upside Amidst Healthcare Innovations - DirectorsTalk Interviews Mon, 13 Oct 2025 07
- TD Cowen Updates Financial Model Citing Upcoming Q4 Results for Lantheus Holdings, Inc. (LNTH) - Finviz Wed, 18 Feb 2026 09
- Lantheus Stock After The Selloff: Breakout Setup Or Value Trap? - AD HOC NEWS ue, 24 Feb 2026 17
- Why Lantheus (LNTH) Stock Is Up Today - Yahoo Finance Fri, 12 Dec 2025 08
- Is Lantheus Holdings (LNTH) Pricing Look Attractive After Recent Short Term Share Rebound - Yahoo Finance Wed, 18 Feb 2026 20
- Why Lantheus (LNTH) Stock Is Falling Today - Yahoo Finance ue, 12 Aug 2025 07
- Why Lantheus (LNTH) Stock Is Falling Today - Yahoo Finance Wed, 06 Aug 2025 07
- Why Lantheus (LNTH) Stock Is Falling Today - Yahoo Finance Wed, 13 Aug 2025 07
- Lantheus (LNTH) Stock Trades Up, Here Is Why - Yahoo Finance Wed, 24 Sep 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 14285 | — | — | Stock Award(Grant) at price 0.00 per share. | HEINO MARY ANNE | Officer and Director | — | 2025-11-17 00:00:00 | D |
| 1 | 3406000 | 191213690 | — | Sale at price 55.34 - 56.15 per share. | FARALLON PARTNERS, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | — | 2025-08-20 00:00:00 | I |
| 2 | 14765 | — | — | Stock Award(Grant) at price 0.00 per share. | DINKELBORG LUDGER | Officer | — | 2025-08-15 00:00:00 | D |
| 3 | 3060 | 163924 | — | Sale at price 53.57 per share. | BLANCHFIELD PAUL | President | — | 2025-08-13 00:00:00 | D |
| 4 | 6000 | 472440 | — | Sale at price 78.74 per share. | NIEDZWIECKI DANIEL M. | General Counsel | — | 2025-06-13 00:00:00 | D |
| 5 | 39773 | 3301296 | — | Sale at price 81.27 - 83.40 per share. | MARSHALL ROBERT J. JR. | Chief Financial Officer | — | 2025-06-09 00:00:00 | D |
| 6 | 5192 | 423771 | — | Sale at price 81.62 per share. | MCHUGH JULIE H | Director | — | 2025-06-09 00:00:00 | D |
| 7 | 14773 | 737616 | — | Conversion of Exercise of derivative security at price 49.93 per share. | MARSHALL ROBERT J. JR. | Chief Financial Officer | — | 2025-06-09 00:00:00 | D |
| 8 | 6599 | 525610 | — | Sale at price 79.65 per share. | BLANCHFIELD PAUL | President | — | 2025-06-05 00:00:00 | D |
| 9 | 6000 | 477900 | — | Sale at price 79.65 per share. | NIEDZWIECKI DANIEL M. | General Counsel | — | 2025-06-05 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -9.84M | 9.60M | -1.03M | 437.85K |
| TaxRateForCalcs | 0.28 | 0.20 | 0.21 | 0.05 |
| NormalizedEBITDA | 551.05M | 444.18M | 86.74M | -33.76M |
| TotalUnusualItems | -35.78M | 46.83M | -4.90M | 8.76M |
| TotalUnusualItemsExcludingGoodwill | -35.78M | 46.83M | -4.90M | 8.76M |
| NetIncomeFromContinuingOperationNetMinorityInterest | 312.44M | 326.66M | 28.07M | -71.28M |
| ReconciledDepreciation | 64.62M | 60.04M | 47.93M | 42.29M |
| ReconciledCostOfRevenue | 545.62M | 586.89M | 353.36M | 237.51M |
| EBITDA | 515.27M | 491.00M | 81.83M | -25.00M |
| EBIT | 450.65M | 430.96M | 33.90M | -67.29M |
| NetInterestIncome | 17.17M | -381.00K | -4.57M | -7.71M |
| InterestExpense | 19.67M | 20.02M | 7.18M | 7.75M |
| InterestIncome | 36.84M | 19.64M | 2.61M | 45.00K |
| NormalizedIncome | 338.38M | 289.44M | 31.94M | -79.60M |
| NetIncomeFromContinuingAndDiscontinuedOperation | 312.44M | 326.66M | 28.07M | -71.28M |
| TotalExpenses | 1.09B | 931.79M | 898.87M | 501.30M |
| TotalOperatingIncomeAsReported | 456.98M | 364.64M | 36.20M | -60.83M |
| DilutedAverageShares | 71.65M | 70.24M | 70.67M | 67.49M |
| BasicAverageShares | 69.20M | 68.27M | 68.49M | 67.49M |
| DilutedEPS | 4.36 | 4.65 | 0.40 | -1.06 |
| BasicEPS | 4.52 | 4.79 | 0.41 | -1.06 |
| DilutedNIAvailtoComStockholders | 312.44M | 326.66M | 28.07M | -71.28M |
| NetIncomeCommonStockholders | 312.44M | 326.66M | 28.07M | -71.28M |
| NetIncome | 312.44M | 326.66M | 28.07M | -71.28M |
| NetIncomeIncludingNoncontrollingInterests | 312.44M | 326.66M | 28.07M | -71.28M |
| NetIncomeContinuousOperations | 312.44M | 326.66M | 28.07M | -71.28M |
| TaxProvision | 118.53M | 84.28M | -1.35M | -3.76M |
| PretaxIncome | 430.98M | 410.94M | 26.72M | -75.04M |
| OtherIncomeExpense | -34.76M | 46.68M | -4.90M | 8.76M |
| OtherNonOperatingIncomeExpenses | 1.02M | -143.00K | ||
| SpecialIncomeCharges | 8.52M | 46.85M | -4.65M | 9.03M |
| GainOnSaleOfPPE | 8.41M | 51.79M | 0.00 | 15.26M |
| OtherSpecialCharges | -106.00K | 4.94M | 4.65M | 6.23M |
| GainOnSaleOfSecurity | -44.30M | -21.00K | -256.00K | -274.00K |
| NetNonOperatingInterestIncomeExpense | 17.17M | -381.00K | -4.57M | -7.71M |
| InterestExpenseNonOperating | 19.67M | 20.02M | 7.18M | 7.75M |
| InterestIncomeNonOperating | 36.84M | 19.64M | 2.61M | 45.00K |
| OperatingIncome | 448.56M | 364.64M | 36.20M | -76.09M |
| OperatingExpense | 539.73M | 344.90M | 545.51M | 263.78M |
| ResearchAndDevelopment | 168.10M | 77.71M | 311.68M | 44.97M |
| SellingGeneralAndAdministration | 371.63M | 267.19M | 233.83M | 218.82M |
| SellingAndMarketingExpense | 177.94M | 141.74M | 100.24M | 68.42M |
| GeneralAndAdministrativeExpense | 193.69M | 125.46M | 133.58M | 150.40M |
| OtherGandA | 193.69M | 125.46M | 133.58M | 150.40M |
| GrossProfit | 988.29M | 709.54M | 581.70M | 187.69M |
| CostOfRevenue | 545.62M | 586.89M | 353.36M | 237.51M |
| TotalRevenue | 1.53B | 1.30B | 935.06M | 425.21M |
| OperatingRevenue | 1.53B | 1.30B | 935.06M | 425.21M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | |
|---|---|---|---|---|
| TreasurySharesNumber | 2.46M | 1.34M | 1.34M | |
| OrdinarySharesNumber | 68.45M | 68.52M | 67.51M | 67.74M |
| ShareIssued | 70.91M | 69.86M | 68.85M | 67.74M |
| NetDebt | 142.41M | 76.25M | ||
| TotalDebt | 619.44M | 616.95M | 583.51M | 191.31M |
| TangibleBookValue | 865.06M | 602.72M | 70.67M | 54.74M |
| InvestedCapital | 1.65B | 1.38B | 1.01B | 639.20M |
| WorkingCapital | 1.09B | 898.47M | 429.92M | 145.29M |
| NetTangibleAssets | 865.06M | 602.72M | 70.67M | 54.74M |
| CapitalLeaseObligations | 53.19M | 54.45M | 25.44M | 16.55M |
| CommonStockEquity | 1.09B | 815.89M | 447.15M | 464.44M |
| TotalCapitalization | 1.65B | 1.38B | 1.00B | 627.56M |
| TotalEquityGrossMinorityInterest | 1.09B | 815.89M | 447.15M | 464.44M |
| StockholdersEquity | 1.09B | 815.89M | 447.15M | 464.44M |
| GainsLossesNotAffectingRetainedEarnings | -1.61M | -1.04M | -1.26M | -485.00K |
| OtherEquityAdjustments | -1.61M | -1.04M | -1.26M | -485.00K |
| TreasuryStock | 175.00M | 75.00M | 75.00M | 0.00 |
| RetainedEarnings | 445.94M | 133.50M | -193.16M | -221.22M |
| AdditionalPaidInCapital | 817.97M | 757.73M | 715.88M | 685.47M |
| CapitalStock | 709.00K | 699.00K | 689.00K | 677.00K |
| CommonStock | 709.00K | 699.00K | 689.00K | 677.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 892.33M | 835.26M | 874.11M | 399.35M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 651.80M | 647.91M | 626.41M | 308.85M |
| OtherNonCurrentLiabilities | 9.99M | 8.87M | 20.71M | 108.35M |
| LongTermDebtAndCapitalLeaseObligation | 618.46M | 616.12M | 583.15M | 179.67M |
| LongTermCapitalLeaseObligation | 53.19M | 54.45M | 25.44M | 16.55M |
| LongTermDebt | 565.28M | 561.67M | 557.71M | 163.12M |
| LongTermProvisions | 23.34M | 22.92M | 22.54M | 20.83M |
| CurrentLiabilities | 240.53M | 187.35M | 247.70M | 90.50M |
| OtherCurrentLiabilities | 11.99M | 11.91M | 125.22M | 5.35M |
| CurrentDebtAndCapitalLeaseObligation | 974.00K | 823.00K | 354.00K | 11.64M |
| CurrentDebt | 974.00K | 823.00K | 354.00K | 11.64M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 48.26M | 36.33M | 30.43M | 22.73M |
| PayablesAndAccruedExpenses | 179.30M | 138.29M | 91.70M | 50.77M |
| CurrentAccruedExpenses | 144.74M | 97.10M | 71.13M | 29.98M |
| Payables | 34.56M | 41.19M | 20.56M | 20.79M |
| AccountsPayable | 34.56M | 41.19M | 20.56M | 20.79M |
| TotalAssets | 1.98B | 1.65B | 1.32B | 863.78M |
| TotalNonCurrentAssets | 653.71M | 565.33M | 643.64M | 627.99M |
| OtherNonCurrentAssets | 8.15M | 9.94M | 15.32M | 29.97M |
| NonCurrentDeferredAssets | 170.23M | 150.20M | 110.65M | 62.76M |
| NonCurrentDeferredTaxesAssets | 170.23M | 150.20M | 110.65M | 62.76M |
| InvestmentsAndAdvances | 39.49M | 0.00 | ||
| InvestmentinFinancialAssets | 39.49M | 0.00 | ||
| AvailableForSaleSecurities | 39.49M | |||
| GoodwillAndOtherIntangibleAssets | 222.95M | 213.17M | 376.47M | 409.70M |
| OtherIntangibleAssets | 161.76M | 151.99M | 315.29M | 348.51M |
| Goodwill | 61.19M | 61.19M | 61.19M | 61.19M |
| NetPPE | 212.88M | 192.02M | 141.20M | 125.56M |
| AccumulatedDepreciation | -108.76M | -107.02M | -100.13M | -88.92M |
| GrossPPE | 321.64M | 299.05M | 241.33M | 214.47M |
| ConstructionInProgress | 27.50M | 40.96M | 14.05M | 10.69M |
| OtherProperties | 36.08M | 45.33M | 19.03M | 8.79M |
| MachineryFurnitureEquipment | 163.06M | 129.84M | 118.47M | 107.99M |
| BuildingsAndImprovements | 85.52M | 73.44M | 76.33M | 73.56M |
| LandAndImprovements | 9.48M | 9.48M | 13.45M | 13.45M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 1.33B | 1.09B | 677.62M | 235.79M |
| OtherCurrentAssets | 9.13M | 246.00K | 205.00K | 2.71M |
| AssetsHeldForSaleCurrent | 0.00 | 7.16M | 0.00 | 0.00 |
| PrepaidAssets | 15.41M | 16.44M | 12.89M | 10.11M |
| Inventory | 68.03M | 64.03M | 35.48M | 35.13M |
| FinishedGoods | 23.07M | 18.96M | 7.25M | 6.58M |
| WorkInProcess | 15.87M | 13.81M | 8.23M | 13.04M |
| RawMaterials | 29.08M | 31.26M | 19.99M | 15.51M |
| Receivables | 321.26M | 284.29M | 213.40M | 89.34M |
| AccountsReceivable | 321.26M | 284.29M | 213.40M | 89.34M |
| AllowanceForDoubtfulAccountsReceivable | -7.80M | |||
| GrossAccountsReceivable | 329.06M | |||
| CashCashEquivalentsAndShortTermInvestments | 912.81M | 713.66M | 415.65M | 98.51M |
| CashAndCashEquivalents | 912.81M | 713.66M | 415.65M | 98.51M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | 465.12M | 258.70M | 263.43M | 41.78M |
| RepurchaseOfCapitalStock | -100.00M | 0.00 | -75.00M | 0.00 |
| RepaymentOfDebt | -318.00K | -717.00K | -175.38M | -43.35M |
| IssuanceOfDebt | 0.00 | 0.00 | 557.75M | 0.00 |
| IssuanceOfCapitalStock | 3.45M | 1.93M | 1.38M | 767.00K |
| CapitalExpenditure | -79.62M | -46.55M | -18.35M | -12.14M |
| InterestPaidSupplementalData | 15.09M | 15.39M | 5.06M | 6.28M |
| IncomeTaxPaidSupplementalData | 153.81M | 151.58M | 54.05M | 215.00K |
| EndCashPosition | 914.49M | 715.28M | 417.24M | 100.65M |
| BeginningCashPosition | 715.28M | 417.24M | 100.65M | 82.69M |
| EffectOfExchangeRateChanges | -998.00K | -93.00K | -335.00K | -310.00K |
| ChangesInCash | 200.20M | 298.14M | 316.93M | 18.27M |
| FinancingCashFlow | -118.54M | -13.06M | 311.69M | -39.33M |
| CashFlowFromContinuingFinancingActivities | -118.54M | -13.06M | 311.69M | -39.33M |
| NetOtherFinancingCharges | -24.95M | -18.09M | -4.59M | -2.05M |
| ProceedsFromStockOptionExercised | 3.28M | 3.82M | 7.54M | 5.29M |
| NetCommonStockIssuance | -96.55M | 1.93M | -73.62M | 767.00K |
| CommonStockPayments | -100.00M | 0.00 | -75.00M | 0.00 |
| CommonStockIssuance | 3.45M | 1.93M | 1.38M | 767.00K |
| NetIssuancePaymentsOfDebt | -318.00K | -717.00K | 382.37M | -43.35M |
| NetLongTermDebtIssuance | -318.00K | -717.00K | 382.37M | -43.35M |
| LongTermDebtPayments | -318.00K | -717.00K | -175.38M | -43.35M |
| LongTermDebtIssuance | 0.00 | 0.00 | 557.75M | 0.00 |
| InvestingCashFlow | -226.01M | 5.94M | -276.55M | 3.68M |
| CashFlowFromContinuingInvestingActivities | -226.01M | 5.94M | -276.55M | 3.68M |
| NetOtherInvestingChanges | -63.14M | 52.49M | -258.20M | 15.82M |
| NetBusinessPurchaseAndSale | -83.25M | 0.00 | 0.00 | 0.00 |
| SaleOfBusiness | 0.00 | |||
| PurchaseOfBusiness | -83.25M | 0.00 | 0.00 | 0.00 |
| NetIntangiblesPurchaseAndSale | -28.00M | 0.00 | 0.00 | |
| PurchaseOfIntangibles | -28.00M | 0.00 | 0.00 | |
| CapitalExpenditureReported | -51.62M | -46.55M | -18.35M | -12.14M |
| OperatingCashFlow | 544.75M | 305.26M | 281.78M | 53.92M |
| CashFlowFromContinuingOperatingActivities | 544.75M | 305.26M | 281.78M | 53.92M |
| ChangeInWorkingCapital | 2.05M | -171.20M | -75.06M | -15.15M |
| ChangeInOtherCurrentAssets | 4.44M | -2.42M | -2.97M | -73.00K |
| ChangeInPayablesAndAccruedExpense | 37.96M | -63.92M | 63.88M | 21.57M |
| ChangeInAccruedExpense | 46.77M | -81.11M | 63.58M | 16.14M |
| ChangeInPayable | -8.80M | 17.19M | 301.00K | 5.42M |
| ChangeInAccountPayable | -8.80M | 17.19M | 301.00K | 5.42M |
| ChangeInInventory | -2.67M | -36.22M | -7.51M | -3.55M |
| ChangeInReceivables | -37.69M | -68.64M | -128.46M | -33.10M |
| ChangesInAccountReceivables | -37.69M | -68.64M | -128.46M | -33.10M |
| OtherNonCashItems | 79.79M | -120.00K | 300.29M | 80.85M |
| StockBasedCompensation | 76.39M | 50.51M | 29.26M | 15.93M |
| UnrealizedGainLossOnInvestmentSecurities | 43.56M | 0.00 | 0.00 | |
| ProvisionandWriteOffofAssets | -904.00K | 7.91M | 7.14M | 4.06M |
| AssetImpairmentCharge | 0.00 | 138.05M | 0.00 | 9.73M |
| DeferredTax | -24.79M | -54.81M | -50.94M | 3.65M |
| DeferredIncomeTax | -24.79M | -54.81M | -50.94M | 3.65M |
| DepreciationAmortizationDepletion | 64.62M | 60.04M | 47.93M | 42.29M |
| DepreciationAndAmortization | 64.62M | 60.04M | 47.93M | 42.29M |
| Depreciation | 64.62M | 60.04M | 47.93M | 42.29M |
| OperatingGainsLosses | -8.41M | -51.79M | -4.91M | -16.15M |
| GainLossOnInvestmentSecurities | -5.49M | |||
| GainLossOnSaleOfPPE | 0.00 | -51.79M | 0.00 | |
| NetIncomeFromContinuingOperations | 312.44M | 326.66M | 28.07M | -71.28M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for LNTH
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|